Information Provided By: 
Fly News Breaks for February 28, 2019
RIGL
Feb 28, 2019 | 20:47 EDT
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $8 price target on Rigel Pharmaceuticals after Q4 results indicated "continued uptake of Tavalisse". The analyst says the company is benefiting from the "improvements in physician awareness and an expanding sales force serving as growth levers that will continue into 2019." Raymond adds that the pipeline efforts of Rigel Pharmaceuticals are on track with its Phase 3 wAIHA trial set to start in the first half of this year.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
